(ALLO) Allogene Therapeutics - Overview
Sector: Healthcare | Industry: Biotechnology | Exchange: NASDAQ (USA) | Market Cap: 670m USD | Total Return: 83.5% in 12m
Avg Turnover: 13.2M
Warnings
Interest Coverage Ratio -147.1 is critical
Altman Z'' -15.00 < 1.0 - financial distress zone
Below Avwap Earnings
Tailwinds
Confidence
Allogene Therapeutics, Inc. is a clinical-stage biotechnology firm focused on the development of allogeneic CAR T cell therapies for oncology and autoimmune disorders. Unlike autologous treatments that require patient-specific cell manufacturing, allogeneic off-the-shelf therapies are derived from healthy donor cells, potentially reducing production costs and treatment wait times.
The company’s pipeline includes cemacabtagene ansegedleucel (cema-cel) for large B-cell lymphoma and ALLO-316 for renal cell carcinoma. It is also expanding into the autoimmune sector with ALLO-329, targeting conditions such as systemic lupus erythematosus and systemic sclerosis. Allogene utilizes proprietary gene editing and protein engineering technologies to minimize graft-versus-host disease risks inherent in donor-derived cell products.
Analyzing the long-term clinical trial data on ValueRay can help clarify the commercial viability of these therapeutic candidates. Headquartered in South San Francisco, the company operates within the high-growth immuno-oncology sector where competitive advantage is driven by manufacturing scalability and intellectual property portfolios.
- Clinical trial data for cema-cel determines path to commercialization for lymphoma
- Expansion into autoimmune disease markets with ALLO-329 impacts long-term valuation
- High cash burn rate necessitates future capital raises or strategic partnerships
- Regulatory approval of allogeneic CAR T platform validates proprietary gene editing technology
- Manufacturing scalability for off-the-shelf therapies drives competitive advantage over autologous treatments
| Net Income: error (cannot be calculated; needs Net Income TTM and Revenue TTM) |
| FCF/TA: -0.32 > 0.02 and ΔFCF/TA 4.62 > 1.0 |
| NWC/Revenue: error (cannot be calculated; needs Current Assets/Liabilities and Revenue current+prev) |
| CFO/TA -0.28 > 3% & CFO -109.2m > Net Income -173.8m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 9.65 > 1.5 & < 3 |
| Outstanding Shares: last quarter (240.3m) vs 12m ago 11.58% < -2% |
| Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin) |
| Asset Turnover: 0.0% > 50% (prev 0.00%; Δ -0.00% > 0%) |
| Interest Coverage Ratio: -147.1 > 6 (EBITDA TTM -168.1m / Interest Expense TTM 1.23m) |
| A: 0.62 (Total Current Assets 273.3m - Total Current Liabilities 28.3m) / Total Assets 396.0m |
| B: -5.19 (Retained Earnings -2.05b / Total Assets 396.0m) |
| C: -0.40 (EBIT TTM -180.2m / Avg Total Assets 452.0m) |
| D: -17.54 (Book Value of Equity -2.05b / Total Liabilities 117.1m) |
| Altman-Z'' = -33.94 = D |
As of May 24, 2026, the stock is trading at USD 2.00 with a total of 4,125,983 shares traded.
Over the past week, the price has changed by +0.00%,
over one month by -16.32%,
over three months by -3.85% and
over the past year by +83.49%.
Allogene Therapeutics has received a consensus analysts rating of 4.43. Therefore, it is recommended to buy ALLO.
- StrongBuy: 8
- Buy: 4
- Hold: 2
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 8.4 | 317.5% |
P/B = 2.4011
Revenue TTM = 0.0 USD
EBIT TTM = -180.2m USD
EBITDA TTM = -168.1m USD
Long Term Debt = 72.6m USD (estimated: total debt 81.1m - short term 8.42m)
Short Term Debt = 8.42m USD (from shortTermDebt, last quarter)
Debt = 81.1m USD (from shortLongTermDebtTotal, last quarter) (leases 83.3m already included)
Net Debt = -185.8m USD (calculated: Debt 81.1m - CCE 266.9m)
Enterprise Value = 483.8m USD (669.6m + Debt 81.1m - CCE 266.9m)
Interest Coverage Ratio = -147.1 (Ebit TTM -180.2m / Interest Expense TTM 1.23m)
EV/FCF = -3.77x (Enterprise Value 483.8m / FCF TTM -128.2m)
FCF Yield = -26.50% (FCF TTM -128.2m / Enterprise Value 483.8m)
FCF Margin = unknown (Revenue TTM is 0 or missing)
Net Margin = unknown
Gross Margin = unknown ((Revenue TTM 0.0 - Cost of Revenue TTM 40.2m) / Revenue TTM)
Tobins Q-Ratio = 1.22 (Enterprise Value 483.8m / Total Assets 396.0m)
Interest Expense / Debt = 1.51% (Interest Expense 1.23m / Debt 81.1m)
Taxrate = 21.0% (US default 21%)
NOPAT = -142.4m (EBIT -180.2m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 8.22 (Total Current Assets 273.3m / Total Current Liabilities 33.3m)
Debt / Equity = 0.29 (Debt 81.1m / totalStockholderEquity, last quarter 278.9m)
Debt / EBITDA = 1.11 (negative EBITDA) (Net Debt -185.8m / EBITDA -168.1m)
Debt / FCF = 1.45 (negative FCF - burning cash) (Net Debt -185.8m / FCF TTM -128.2m)
Total Stockholder Equity = 307.8m (last 4 quarters mean from totalStockholderEquity)
RoA = -38.45% (Net Income -173.8m / Total Assets 396.0m)
RoE = -7.36% (Net Income TTM -173.8m / Total Stockholder Equity 2.36b)
RoCE = -7.41% (EBIT -180.2m / Capital Employed (Equity 2.36b + L.T.Debt 72.6m))
RoIC = -45.27% (negative operating profit) (NOPAT -142.4m / Invested Capital 314.5m)
WACC = 9.55% (E(669.6m)/V(750.7m) * Re(10.56%) + D(81.1m)/V(750.7m) * Rd(1.51%) * (1-Tc(0.21)))
Discount Rate = 10.56% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 95.56 | Cagr: 17.14%
[DCF] Fair Price = unknown (Cash Flow -128.2m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 0.78 | # QB: 0
Revenue Correlation: N/A | Revenue CAGR: N/A | SUE: N/A | # QB: 0
EPS current Quarter (2026-06-30): EPS=-0.15 | Chg30d=+17.36% | Revisions=+33% | Analysts=6
EPS next Quarter (2026-09-30): EPS=-0.16 | Chg30d=+10.68% | Revisions=+33% | Analysts=7
EPS current Year (2026-12-31): EPS=-0.66 | Chg30d=+3.67% | Revisions=+33% | GrowthEPS=+22.8% | GrowthRev=+0.0%
EPS next Year (2027-12-31): EPS=-0.80 | Chg30d=-6.82% | Revisions=+20% | GrowthEPS=-21.9% | GrowthRev=+80214.8%
[Analyst] Revisions Ratio: +33%